Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl-xL inhibition.

Nguyen TTT, Ishida CT, Shang E, Shu C, Torrini C, Zhang Y, Bianchetti E, Sanchez-Quintero MJ, Kleiner G, Quinzii CM, Westhoff MA, Karpel-Massler G, Canoll P, Siegelin MD.

EMBO Mol Med. 2019 Oct;11(10):e10769. doi: 10.15252/emmm.201910769. Epub 2019 Aug 29.

2.

Activation of LXR Receptors and Inhibition of TRAP1 Causes Synthetic Lethality in Solid Tumors.

Nguyen TTT, Ishida CT, Shang E, Shu C, Bianchetti E, Karpel-Massler G, Siegelin MD.

Cancers (Basel). 2019 Jun 7;11(6). pii: E788. doi: 10.3390/cancers11060788.

3.

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.

Shang E, Zhang Y, Shu C, Ishida CT, Bianchetti E, Westhoff MA, Karpel-Massler G, Siegelin MD.

Sci Rep. 2018 Oct 18;8(1):15383. doi: 10.1038/s41598-018-33784-2.

4.

Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.

Ishida CT, Zhang Y, Bianchetti E, Shu C, Nguyen TTT, Kleiner G, Sanchez-Quintero MJ, Quinzii CM, Westhoff MA, Karpel-Massler G, Prabhu VV, Allen JE, Siegelin MD.

Clin Cancer Res. 2018 Nov 1;24(21):5392-5406. doi: 10.1158/1078-0432.CCR-18-1040. Epub 2018 Jul 23.

5.

Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.

Zhang Y, Ishida CT, Ishida W, Lo SL, Zhao J, Shu C, Bianchetti E, Kleiner G, Sanchez-Quintero MJ, Quinzii CM, Westhoff MA, Karpel-Massler G, Canoll P, Siegelin MD.

Clin Cancer Res. 2018 Aug 15;24(16):3941-3954. doi: 10.1158/1078-0432.CCR-18-0260. Epub 2018 May 15.

6.

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.

Zhang Y, Ishida CT, Shu C, Kleiner G, Sanchez-Quintero MJ, Bianchetti E, Quinzii CM, Westhoff MA, Karpel-Massler G, Siegelin MD.

Sci Rep. 2018 May 9;8(1):7373. doi: 10.1038/s41598-018-25802-0.

7.

IDH1 R132H predicts sensitivity to Bcl-xL inhibition-mediated programmed cell death.

Karpel-Massler G, Ishida CT, Siegelin MD.

Oncotarget. 2017 Dec 18;9(1):1-2. doi: 10.18632/oncotarget.23399. eCollection 2018 Jan 2. No abstract available.

8.

Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.

Karpel-Massler G, Ishida CT, Bianchetti E, Zhang Y, Shu C, Tsujiuchi T, Banu MA, Garcia F, Roth KA, Bruce JN, Canoll P, Siegelin MD.

Nat Commun. 2017 Oct 20;8(1):1067. doi: 10.1038/s41467-017-00984-9.

9.

Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.

Karpel-Massler G, Ishida CT, Zhang Y, Halatsch ME, Westhoff MA, Siegelin MD.

Expert Opin Drug Discov. 2017 Oct;12(10):1031-1040. doi: 10.1080/17460441.2017.1356286. Epub 2017 Jul 20. Review.

10.

BET-inhibitors as sensitizers for BH3-mimetics.

Ishida CT, Karpel-Massler G, Siegelin MD.

Aging (Albany NY). 2017 Jun 26;9(6):1475-1476. doi: 10.18632/aging.101259. No abstract available.

11.

Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.

Karpel-Massler G, Ishida CT, Bianchetti E, Shu C, Perez-Lorenzo R, Horst B, Banu M, Roth KA, Bruce JN, Canoll P, Altieri DC, Siegelin MD.

Cancer Res. 2017 Jul 1;77(13):3513-3526. doi: 10.1158/0008-5472.CAN-16-3424. Epub 2017 May 18.

12.

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.

Ishida CT, Bianchetti E, Shu C, Halatsch ME, Westhoff MA, Karpel-Massler G, Siegelin MD.

Oncotarget. 2017 May 2;8(18):29558-29573. doi: 10.18632/oncotarget.16365.

13.

Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.

Ishida CT, Shu C, Halatsch ME, Westhoff MA, Altieri DC, Karpel-Massler G, Siegelin MD.

Oncotarget. 2017 Jun 6;8(23):37140-37153. doi: 10.18632/oncotarget.16202.

Supplemental Content

Loading ...
Support Center